108 BioCapital Leads $4 Million Investment in SedMed

The capital injection will fuel SedMed’s efforts to broaden its commercial reach and strengthen channel partnerships. For the Milford, Connecticut-based manufacturer, the funding arrives as the company seeks to transition its flagship product—a mechanical, adjustable sit-to-stand assist—from a clinical staple into a mainstream home-care solution. CEO Jeremy Bronen noted that the partnership with 108 BioCapital will also facilitate hospital-based studies to further validate the device's impact on patient safety and caregiver strain.

Investors at 108 BioCapital highlighted the product's simplicity as a key market advantage. Because the lift requires no electricity, batteries, or specialized installation, the firm sees significant potential for adoption in emerging markets, specifically identifying India as a target for future growth. By focusing on environmental barriers that cause accidents for older adults, the company aims to solidify its position as a provider of accessible, low-maintenance mobility solutions.